{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse.00206:a retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahse.00206%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.004282,
    "timestamp_received": "2026-04-25T14:12:49.933687+00:00Z",
    "timestamp_returned": "2026-04-25T14:12:49.937969+00:00Z",
    "trace_id": "b22fc1b4-2cff-4c9a-8470-64b0f8631c42"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:hse.00206:a",
      "indication": "Treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (i) Received prior therapy for locally advanced or metastatic disease, or (ii) Developed disease recurrence during or within six months of completing adjuvant therapy.",
      "initial_approval_date": "2015-09-15",
      "initial_approval_url": null,
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either (i) received prior therapy for locally advanced or metastatic disease or (ii) developed disease recurrence during or within six months of completing adjuvant therapy.",
      "raw_biomarkers": null,
      "raw_cancer_type": "locally advanced or metastatic breast cancer",
      "raw_therapeutics": "Trastuzumab Emtansine",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hse.00206",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Trastuzumab Emtansine (Kadcyla) - 21 days. NCCP National SACT Regimen. HSE.",
        "title": null,
        "aliases": [],
        "description": "Trastuzumab Emtansine (Kadcyla) - 21 days, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6547/206_v4_Trastuzumab_Emtansine_21days.pdf",
        "urls": [
          "https://healthservice.hse.ie/documents/6547/206_v4_Trastuzumab_Emtansine_21days.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hse",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Service Executive",
              "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": null,
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": null,
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": null,
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2017-09-20",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}